We are back with another Update Course Rewind video! This time we are presenting you updates in "Staging and Management of Neuroblastoma" with Dr. Paul Jeziorczak from APSA Professional Development Committee.
Host: Ellen Encisco
Type: video · posted 2023-06-08 Canonical: https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710 ## Chapters - [0:00](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=0) Case Presentation - [0:24](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=24) Updated COG Risk Stratification - [1:12](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=72) Closing Remarks ## Statements - "The presented case is a 16-month-old with a right adrenal mass measuring 8 centimeters" (clinical) [0:00](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=0) - "Biopsy showed favorable cell neuroblastoma biology with no MYCN amplification but with segmental chromosomal abnormalities" (clinical) [0:00](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=0) - "The Children's Oncology Group neuroblastoma classification tree is constantly changing as new information is added" — Paul Yasurjak (guideline) [0:24](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=24) - "Based on the 2021 COG classification, the presented tumor would be classified as higher risk" — Paul Yasurjak (guideline) [0:24](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=24) - "COG reviewed patients enrolled in trials between 2007 and 2017" — Paul Yasurjak (epidemiological) [0:24](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=24) - "The presence of segmental chromosomal aberrations such as loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes" — Paul Yasurjak (clinical) [0:24](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=24) - "The updated schema classifies tumors as high risk when there is no MYCN amplification but segmental chromosomal abnormalities are present" — Paul Yasurjak (guideline) [0:24](https://library.globalcastmd.com/watch/update-course-rewind-staging-and-management-of-neuroblastoma-2022-6710?t=24) --- Not medical advice · citation policy: https://library.globalcastmd.com/ai